Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TIM3 Signaling in Effector T Cells Acts as an Immunometabolic Switch in the Purine Degradation Pathway to Suppress Intestinal Inflammation.

Gastroenterology·2026
Same author

Author Correction: Regulatory T cells in the mouse hypothalamus control immune activation and ameliorate metabolic impairments in high-calorie environments.

Nature communications·2026
Same author

Targeting the transcription factor GATA3 by the DNAzyme formulation SB012 in patients with moderately-to-severely active ulcerative colitis: a multicenter, randomized, placebo-controlled, phase 2a induction trial.

Inflammatory bowel diseases·2026
Same author

Early Gut-Vascular Barrier Breakdown Precedes Colitis Onset in Murine Models.

Cellular and molecular gastroenterology and hepatology·2026
Same author

Celastrol attenuates Th1- and Th2-driven skin inflammation in 2D and 3D in vitro models.

Scientific reports·2026
Same author

Bioinspired, Guanidinium, and Indole Modified Poly(glycidyl ether)s as Highly Efficient Vectors for Polyplex-Mediated Gene Delivery.

Macromolecular rapid communications·2026

Related Experiment Video

Updated: Aug 19, 2025

Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

11.0K

Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies.

Michael Gabel1,2, Annkathrin Knauss1,2, Dagmar Fischer3

  • 1Medical Clinic I, Research Campus, University Hospital of Erlangen, Hartmannstraße 14, 91052 Erlangen, Germany.

International Journal of Molecular Sciences
|November 26, 2022
PubMed
Summary

Small interfering RNA (siRNA) holds promise for gene therapy, but delivery challenges persist. Surface-modified nanoparticles, particularly with antibodies, offer a promising strategy for enhanced siRNA delivery and therapeutic efficacy.

Keywords:
antibodygene deliverylipid nanoparticlepolymer nanoparticlesiRNAsurface-functionalized nanoparticlestargeted drug delivery

More Related Videos

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

7.6K
Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery
08:53

Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery

Published on: April 16, 2019

7.7K

Related Experiment Videos

Last Updated: Aug 19, 2025

Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

11.0K
Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

7.6K
Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery
08:53

Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery

Published on: April 16, 2019

7.7K

Area of Science:

  • Biotechnology
  • Nanomedicine
  • Molecular Biology

Background:

  • RNA interference (RNAi) and small interfering RNA (siRNA) show therapeutic potential for genetic diseases.
  • Current siRNA therapies face limitations including poor stability, cellular uptake, immune response, and target specificity.
  • Nanoparticulate drug delivery systems offer solutions to overcome these siRNA limitations.

Purpose of the Study:

  • To review the function and targeted delivery of siRNA nanoparticles.
  • To highlight surface modification strategies for improved siRNA delivery.
  • To discuss the therapeutic effects of these advanced delivery systems.

Main Methods:

  • Exploration of surface-modified siRNA nanoparticles.
  • Focus on antibody-mediated surface modification for targeted delivery.
  • Analysis of lipid- and polymer-based nanoparticle components.

Main Results:

  • Surface modification enhances siRNA distribution to target sites.
  • Antibody functionalization improves specificity and safety of siRNA delivery.
  • Nanoparticle strategies address key limitations of naked siRNA.

Conclusions:

  • Surface-modified siRNA nanoparticles represent a significant advancement in targeted gene therapy.
  • Further development is crucial to overcome challenges in efficient and safe delivery.
  • These systems hold promise for treating a range of diseases caused by gene defects.